metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |
mNSCLC - L2 - EGFR mutant | |
durvalumab plus osimertinib | CAURAL ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -